

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	CATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/809,075	10/809,075 03/25/2004		Ken-Shwo Dai	U 015086-3	8634		
140	7590	06/30/2006	EXAMINER				
	& PARRY	eran.	FRONDA, CHRISTIAN L				
26 WEST 61ST STREET NEW YORK, NY 10023				ART UNIT	PAPER NUMBER		
	•		1652				
			DATE MAILED: 06/30/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati	on No.	Applicant(s)				
			75	DAI, KEN-SHWO				
	Office Action Summary	Examine	r	Art Unit				
		Christian	L. Fronda	1652				
Period fo	The MAILING DATE of this communicati or Reply	on appears on th	over sheet with the	correspondence ad	dress			
WHI(- Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MAILInsions of time may be available under the provisions of 37 SIX (6) MONTHS from the mailing date of this communical period for reply is specified above, the maximum statutory are to reply within the set or extended period for reply will, be reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	NG DATE OF THE CFR 1.136(a). In no evition. In period will apply and way statute, cause the app	HIS COMMUNICATION ent, however, may a reply be ill expire SIX (6) MONTHS fro clication to become ABANDON	ON. timely filed om the mailing date of this co NED (35 U.S.C. § 133).				
Status								
1)	Responsive to communication(s) filed or	າ						
2a) <u></u> ☐	This action is FINAL . 2b)	☐ This action is r	ion-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims							
4)⊠	Claim(s) 1-15 is/are pending in the appli	cation.						
	4a) Of the above claim(s) <u>1 and 7-15</u> is/are withdrawn from consideration.							
5)	Claim(s) is/are allowed.							
6)⊠	Claim(s) <u>2-6</u> is/are rejected.							
7)	Claim(s) is/are objected to.							
8)□	Claim(s) are subject to restriction	and/or election r	equirement.					
Applicat	on Papers							
9)[The specification is objected to by the Ex	aminer.						
	The drawing(s) filed on 25 March 2004 is		oted or b) objected	to by the Examiner				
	Applicant may not request that any objection	to the drawing(s) t	e held in abeyance. S	see 37 CFR 1.85(a).				
	Replacement drawing sheet(s) including the	соггесtion is requir	ed if the drawing(s) is o	bjected to. See 37 CF	FR 1.121(d).			
11)	The oath or declaration is objected to by	the Examiner. No	ote the attached Offic	ce Action or form PT	O-152.			
Priority (ınder 35 U.S.C. § 119							
	Acknowledgment is made of a claim for for All b) Some * c) None of:			(a)-(d) or (f).				
	1. Certified copies of the priority documents have been received.							
	 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage 							
				ved in this National	Stage			
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
		a not of the cort	med depies not receive	veu.				
Attachmen	t(s)							
	e of References Cited (PTO-892)		4) Interview Summa	rv (PTO-413)				
2) 🔲 Notic	e of Draftsperson's Patent Drawing Review (PTO-9		Paper No(s)/Mail	Date				
	nation Disclosure Statement(s) (PTO-1449 or PTO/ r No(s)/Mail Date <u>3/04, 8/05</u> .	(SB/08)	5) Notice of Informal 6) Other:	Patent Application (PTC) - 152)			

DETAILED ACTION

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claim 1, drawn to a polypeptide, classified in class 530, subclass 350.
 - II. Claims 2-6, drawn to an isolated polynucleotide, host cell, and method for recombinantly producing a polypeptide, classified in class 435, subclass 69.1.
 - III. Claims 7 and 8, drawn to an isolated antibody, classified in class 424, subclass 130.1.
 - IV. Claims 9-11, drawn to a method for detecting the presence of an isolated nucleic acid encoding an isolated polypeptide, classified in class 435, subclass 91.2.
 - V. Claims 12-15, drawn to a method for detecting the presence of an isolated polypeptide, classified in class 435, subclass 6.
- 2. The inventions are distinct, each from the other because of the following reasons:
 Inventions of Groups I-III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). Each of the products of Groups I-III are independent chemical entities and require different literature searches.

Inventions of Groups IV and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). The processes of Groups IV and V are patentably distinct because they require different process steps, reagents, and parameters; have different purposes; and produce different products.

Inventions II and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that product such as using the polynucleotide in a process for recombinantly producing a polypeptide.

Inventions III and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the

product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that product such as using the antibody in a chromatographic process for purifying a polypeptide.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

- 3. During a telephone conversation with Clifford J. Mass on 06/19/2006, a provisional election was made with traverse to prosecute the invention of Group II, claims 2-6. Affirmation of this election must be made by applicant in replying to this Office action. Claims 1 and 8-15 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).
- 5. Claims 2-6 are under consideration in this Office Action.

Claim Rejections - 35 U.S.C. § 101

- 6. 35 U.S.C. 101 reads as follows:
 - Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
- 7. Claims 2-6 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific or substantial asserted utility or a well established utility.

Applicants disclose the nucleotide sequences of SEQ ID NO: 1 and the deduced amino acid sequence of the protein encoded as the amino acid sequence of SEQ ID NO: 2. Applicants disclose that based on homology searches that the protein of SEQ ID NO: 2 is a "variant" of a serine threonine protein kinase, which is a generic asserted utility. It is not clear from the specification if the protein consisting of SEQ ID NO: 2 actually has the same enzyme activity

and/or biological function as a serine threonine protein kinase. The specification does not specifically disclose the specific biological function of the protein of SEQ ID NO: 2 or its relationship to any disease. It appears that the main utility of the nucleic acid and protein is to carry out further research to identify the biological function and possible diseases associated with the protein.

According to MPEP 2107.01, a "specific utility" is specific to the subject matter claimed which contrasts with a general utility that would be applicable to the broad class of the invention. "Substantial utility" is one that provides a specific benefit in currently available form at the time of filing of the invention. Substantial utility defines a "real world" use. Utilities that require or constitute carrying out further research to identify and/or reasonably confirm a specific use are not substantial and do not provide a specific benefit.

Thus, in view of the above considerations the claimed invention is not supported by either a specific or substantial asserted utility or a well established utility.

Claim Rejections - 35 U.S.C. § 112, 1st Paragraph

- 8. The following is a quotation of the first paragraph of 35 U.S.C. 112:

 The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 9. Claims 2-6 are rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific or substantial utility or a well established utility for the reasons set forth above in the rejection of claims 2-6 under 35 U.S.C. 101, one skilled in the art clearly would not know how to use the claimed invention.

Conclusion

- 10. No claim is allowed.
- 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272-0929. The examiner can normally be reached Monday-Friday between 9:00AM 5:00PM. If attempts to

reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura N Achutamurthy can be reached on (571)272-0928. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.

12. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

CLF

TEKCHAND SAIDHA